Veru enrolls first patients in Phase 2b trial of enobosarm, semaglutide

Veru announced that it has enrolled the first patients in its Phase 2b clinical trial of enobosarm, an oral selective androgen receptor modulator, SARM, to avoid muscle loss and to augment fat loss when combined with semaglutide, a Glucagon-like peptide-1 receptor agonist drug, for potentially higher quality weight loss. Topline clinical data is expected in the fourth quarter of the calendar year 2024. “We are excited to enroll the first patients in the Phase 2b clinical trial, marking an important milestone in the development of enobosarm for high quality weight loss,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc. “There is a significant unmet medical need to have a drug that may effectively preserve muscle in patients undergoing weight loss therapy with GLP-1 drugs. Patients receiving GLP-1 drugs lose significant muscle as part of the weight loss which can lead to muscle weakness in older patients with both obesity and low muscle reserves. Muscle weakness is associated with mobility disability and loss of balance resulting in a higher risk for falls and hip and pelvic fractures. In fact, the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes clinical trial to highlight the four-fold increase in pelvic and hip fractures that was observed in patients greater than 75 years of age receiving Wegovy compared to placebo.”